UltraShape manufactures a non-invasive body contouring device that eliminates adipose tissue (fat cells). The company's first product, Contour 1, uses ultrasound to liquidate fat cells. The device is being positioned as an alternative to liposuction. In July the company obtained EU CE clearance for the device.
However, some medical authorities question whether the ultrasound waves that are used in the company's systems may harm other parts of the body, other than the fat which it aims to destroy.
However, should longer term use prove its efficacy the company would stand to make major inroads into a massive market.
Founded in 2000, UltraShape has 53 employees. Its founders are Dr. Ami Glicksman, formerly a plastic surgeon at Sheba Medical Center at Tel Hashomer, who serves as company president, and Eshel, a physicist and an ultrasound expert.
The controversial Israeli start-up UltraShape Ltd. is nearing the closing of a $15 million financing round from Israel Seed Partners, and two US financial institutions. UltraShape has raised $12 million to date in three financing rounds. Israel Seed Partners was the sole investor in the last round, investing $6 million in the company.